References Ian J Neeland, Jennifer Linge, Andreas L Birkenfeld, 2024, Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies pubmed.ncbi.nlm.nih.gov/38937282/ Allison B Reiss, Shelly Gulkarov, Raymond Lau, Stanislaw P Klek , Ankita Srivastava, Heather A Renna, Joshua De Leon, 2025, Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss Todd Miller, Stephanie Mull, Alan Albert Aragon, James Krieger, Brad Jon Schoenfeld, 2018, Resistance Training Combined With Diet Decreases Body Fat While Preserving Lean Mass Independent of Resting Metabolic Rate: A Randomized Trial Guidepoint Qsight, 2025, GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024 Tatiana Bido, 2024, New Report Tracks GLP-1s Impact on Plastic Surgery and Beauty Spending During Election Year Val Brickates Kennedy, 2024, Survey finds GLP-1 users more inclined to get aesthetic procedures AAFPRS Reveals New Statistics and Trends in Facial Plastic Surgery, 2025 Jessica Weiser, MD Ready to discover how Sofwave can transform your aesthetic practice

The Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist were followed, which is found in the supplementary material (p6)
These substrates are notably neither chromatinized nor fully restricted to nuclei upon introduction into cells, and we cannot exclude the possibility that this impacts the extent our observations can be generalized to chromosomal repair
Subcutaneous injection, commonly at night
External resources National Institutes of Health - GLP-1 Physiology and Pharmacology FDA Consumer Update on Products Marketed as GLP-1 Alternatives Nature Reviews Gastroenterology - Gut Microbiome and Incretin Hormones In case I do not see you, good afternoon, good evening, and good night